<DOC>
	<DOCNO>NCT03074513</DOCNO>
	<brief_summary>The goal clinical research study learn atezolizumab bevacizumab help control rare solid tumor .</brief_summary>
	<brief_title>Atezolizumab Bevacizumab Rare Solid Tumors</brief_title>
	<detailed_description>Study Drug Administration : Each cycle 21 day . On Day 1 cycle , receive atezolizumab bevacizumab vein 60 minute . Length Treatment : You may continue take study drug long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study follow-up visit . Study Visits : On Day 1 every odd-numbered cycle ( Cycles 1 , 3 , 5 , ) : °°You physical exam . Blood ( 4 teaspoon ) draw routine test learn certain genetic mutation ( change ) may affect response study drug . °Urine collect routine test . On Day 1 every even-numbered cycle ( Cycles 2 , 4 , 6 , ) : - You physical exam . - Blood ( 4 teaspoon ) draw routine testing . - During Cycle 2 , blood ( 2 teaspoon ) draw dose study drug biomarker test . - During Cycle 2 , image-guided core biopsy check status disease biomarker test . On Day 8 Cycles 1 Cycle 2 : - You physical exam . - Blood ( 2 teaspoon ) draw routine testing . Every 9-12 week , MRI CT scan . At time doctor think need , EKG either ECHO MUGA scan . End-of-Treatment Visit : About 30 day last dose study drug : - You physical exam . - Blood ( 2 teaspoon ) draw routine test . If disease get bad , sample also use biomarker test . - If disease get bad , image-guided core biopsy check status disease . Follow-Up : About every 3 month end-of-treatment visit , family/caregiver call study staff ask . This call last 15 minute . The study staff may also access medical record publically available record learn long-term health status . This investigational study . Atezolizumab FDA approve commercially available treatment metastatic ( spread ) non-small cell lung cancer ( NSCLC ) . Bevacizumab FDA approve commercially available treatment metastatic colorectal cancer , metastatic non-squamous NSCLC , metastatic renal cell carcinoma , recurrent ( come back treatment ) glioblastoma , cervical cancer , platinum-resistant ( type chemotherapy ) recurrent epithelial ovarian , fallopian tube primary peritoneal cancer . The combination drug treat type cancer consider investigational . The study doctor explain study drug design work . Up 160 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lip Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Signed Informed Consent Form 2 . Age &gt; /= 18 year 3 . Ability comply study protocol , investigator 's judgment 4 . Measurable disease accord RECIST v1.1 . Previously irradiate lesion consider measurable disease progressive disease unequivocally document site since radiation . 5 . ECOG Performance Status 0 1 6 . Adequate hematologic endorgan function , define follow laboratory test result , obtain within 14 day prior initiation study treatment : ANC &gt; /= 1.5 x 10 ( 9 ) /L without granulocyte colonystimulating factor support ; Lymphocyte count &gt; /= 0.5 x 10 ( 9 ) /L ; Platelet count &gt; /= 100 x 10 ( 9 ) /L without transfusion ; WBC Count &gt; /= 2500/ul ; Hemoglobin &gt; /= 90 g/L [ Patients may transfuse meet criterion ] ; AST , ALT , alkaline phosphatase ( ALP ) &lt; /= 2.5 x upper limit normal ( ULN ) , follow exception : Patients document liver metastasis : AST ALT &lt; /= 5 x ULN Patients document liver bone metastasis : ALP &lt; /= 5 x ULN Serum bilirubin ≤ 1.5 x ULN Serum creatinine &lt; /= 1.5 x ULN Serum albumin &gt; /= 2.5 g/dL For patient receive therapeutic anticoagulation : INR aPTT &lt; /= 1.5 x ULN 7 . For patient receive therapeutic anticoagulation : stable anticoagulant regimen 8 . For woman childbearing potential : agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive method failure rate &lt; 1 % per year treatment period 6 month last dose study treatment . 9 . ( cont . ) A woman consider childbearing potential postmenarcheal , reach postmenopausal state ( &gt; /= 12 continuous month amenorrhea identify cause menopause ) , undergone surgical sterilization ( removal ovary and/or uterus ) . Examples contraceptive method failure rate &lt; 1 % per year include bilateral tubal ligation , male sterilization , hormonal contraceptive inhibit ovulation , hormonereleasing intrauterine device , copper intrauterine device . The reliability sexual abstinence evaluate relation duration clinical trial prefer usual lifestyle patient . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . 10 . Appendiceal adenocarcinoma basket 1 . Metastatic appendiceal adenocarcinoma 2 . Not consider candidate curative surgery 11 . EpsteinBarr Virusassociated nasopharyngeal carcinoma basket a. Metastatic locally recurrent disease amenable curative intent treatment b. EBV positive EBV encode small RNA situ hybridization ( EBER ISH ) c. Any number prior therapy , include 0 12 . Human Papilloma Virusassociated cancer a. Histologically proven squamous carcinoma anal canal , penile , vaginal , vulva , refractory cervical cancer progress least one treatment regimen include cisplatin carboplatin enrol . HPV confirmation require . b . Patients must metastatic disease amenable surgical resection . c. If HIV+ positive , patient infect Human Immunodeficiency Virus ( HIV ) CD4+ T cell count &gt; 400 cells/mm3 may eligible study . d. Patients coinfected hepatitis B virus and/or hepatitis C virus may include study provide liver function test remain within limit list . Patients must follow hepatologist course study . 13 . Merkel Cell Carcinoma basket a. Metastatic locally recurrent disease amenable curative intent treatment b . Any number prior therapy , include 0 14 . Neuroendocrine tumor , pancreatic basket 1 . Grade 1 grade 2 accord review pathologist 2 . Progressive disease precede 12 month 3 . Any number prior therapy , include 0 4 . Patients use somatostatin analogue symptom control must stable dos 56 day prior enrollment . 15 . Neuroendocrine tumor , extrapancreatic basket 1 . Grade 1 grade 2 accord review pathologist 2 . Progressive disease precede 12 month 3 . Any number prior therapy , include 0 4 . Patients use somatostatin analogue symptom control must stable dos 56 day prior enrollment . 16 . Peritoneal mesothelioma basket a. Refractory platinum pemetrexed systemic therapy b . Any number prior therapy 17 . Pleural mesothelioma basket 1 . Metastatic locally recurrent disease amenable curative intent treatment 2 . Refractory platinum pemetrexed systemic therapy 3 . Any number prior therapy 1 . Treatment study cancer within 28 day prior initiation study treatment 2 . Treatment investigational therapy within 28 day prior initiation study treatment 3 . History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion proteins 4 . Known hypersensitivity biopharmaceutical agent produce Chinese hamster ovary cell 5 . Known allergy hypersensitivity component atezolizumab formulation 6 . Known allergy hypersensitivity component bevacizumab formulation 7 . Active history autoimmune disease immune deficiency , include , limited , myasthenia gravis , myositis , autoimmune hepatitis , systemic lupus erythematosus , rheumatoid arthritis , inflammatory bowel disease , antiphospholipid antibody syndrome , Wegener granulomatosis , Sjögren 's syndrome , GuillainBarré syndrome , multiple sclerosis , follow exception : 8 . ( cont . ) Patients history autoimmunerelated hypothyroidism thyroid replacement hormone eligible study . Patients control Type 1 diabetes mellitus insulin regimen eligible study . Patients eczema , psoriasis , lichen simplex chronicus , vitiligo dermatologic manifestation ( e.g. , patient psoriatic arthritis exclude ) eligible study provide follow condition meet : Rash must cover &lt; 10 % body surface area Disease well control baseline require lowpotency topical corticosteroid No occurrence acute exacerbation underlie condition require psoralen plus ultraviolet A radiation , methotrexate , retinoids , biologic agent , oral calcineurin inhibitor , high potency oral corticosteroid within previous 12 month 9 . Prior allogeneic stem cell solid organ transplantation 10 . History idiopathic pulmonary fibrosis , organize pneumonia ( e.g. , bronchiolitis obliterans ) , druginduced pneumonitis , idiopathic pneumonitis , evidence active pneumonitis screen chest compute tomography ( CT ) scan . ( History radiation pneumonitis radiation field ( fibrosis ) permit ) 11 . Positive HIV test screening ( except cohort 3 , HPVassociated cancer ) 12 . Except cohort 3 , HPVassociated cancer , active hepatitis B virus ( HBV ) infection ( chronic acute ) , define positive hepatitis B surface antigen ( HBsAg ) test screening . Patients past resolve HBV infection , define negative HBsAg test positive total hepatitis B core antibody ( HBcAb ) test negative HBV DNA test screening , eligible study . 13 . Except cohort 3 , HPVassociated cancer active hepatitis C virus ( HCV ) infection , define positive HCV antibody test follow positive HCV RNA test screening . The HCV RNA test perform patient positive HCV antibody test . 14 . Active tuberculosis 15 . Severe infection within 4 week prior initiation study treatment , include , limited , hospitalization complication infection , bacteremia , severe pneumonia 16 . Treatment therapeutic oral IV antibiotic within 2 week prior initiation study treatment . Patients receive prophylactic antibiotic ( e.g. , prevent urinary tract infection chronic obstructive pulmonary disease exacerbation ) eligible study . 17 . Significant cardiovascular disease , New York Heart Association cardiac disease ( Class II great ) , myocardial infarction , cerebrovascular accident within 3 month prior initiation study treatment , unstable arrhythmia , unstable angina 18 . Major surgical procedure diagnosis within 4 week prior initiation study treatment , anticipation need major surgical procedure course study 19 . Treatment live , attenuated vaccine within 4 week prior initiation study treatment , anticipation need vaccine course study , 5 month follow anticipate last dose atezolizumab . 20 . Malignancies disease study within 5 year prior Cycle 1 , Day 1 , exception negligible risk metastasis death expect curative outcome ( adequately treat carcinoma situ cervix , basal squamous cell skin cancer , ductal carcinoma situ treat surgically curative intent ) undergo active surveillance per standardofcare management ( e.g. , chronic lymphocytic leukemia Rai Stage 0 ) 21 . Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find contraindicates use investigational drug , may affect interpretation result , may render patient high risk treatment complication 22 . Prior treatment CD137 agonists immune checkpoint blockade therapy , include anti－CTLA4 , anti－PD1 , anti－PDL1 therapeutic antibody 23 . Treatment systemic immunostimulatory agent ( include , limited , interferon interleukin 2 [ IL2 ] ) within 4 week five halflives drug ( whichever longer ) prior initiation study treatment 24 . Treatment systemic immunosuppressive medication ( include , limited , corticosteroid , cyclophosphamide , azathioprine , methotrexate , thalidomide , anti－TNFα agent ) within 2 week prior initiation study treatment , anticipation need systemic immunosuppressive medication course study , follow exception : Patients receive lowdose immunosuppressant medication eligible study . Patients receive mineralocorticoid ( e.g. , fludrocortisone ) , corticosteroids chronic obstructive pulmonary disease ( COPD ) asthma , lowdose corticosteroid orthostatic hypotension adrenal insufficiency eligible study . 25 . Pregnant breastfeeding , intend become pregnant study . Women childbearing potential must negative serum pregnancy test result within 14 day prior initiation study treatment . 26 . Inadequately control hypertension ( define systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg ) . Antihypertensive therapy maintain systolic blood pressure &lt; 150 mmHg and/or diastolic blood pressure &lt; 100 mmHg permit . 27 . Prior history hypertensive crisis hypertensive encephalopathy 28 . History stroke transient ischemic attack within 6 month prior Cycle 1 , Day 1 29 . Significant vascular disease ( e.g. , aortic aneurysm require surgical repair recent peripheral arterial thrombosis ) within 6 month prior Cycle 1 , Day 1 30 . Patients baseline ECG demonstrate QTc &gt; 460 m 31 . Evidence bleed diathesis clinically significant coagulopathy ( absence therapeutic anticoagulation ) 32 . Current recent ( within 10 calendar day prior Cycle 1 , Day 1 ) use dipyramidole , ticlopidine , clopidogrel , cilostazol 33 . Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 calendar day prior first dose bevacizumab 34 . History abdominal tracheoesophageal fistula gastrointestinal perforation within 6 month prior Cycle 1 , Day 1 35 . Clinical sign symptoms gastrointestinal obstruction requirement routine parenteral hydration , parenteral nutrition , tube feed 36 . Evidence abdominal free air explain paracentesis recent surgical procedure 37 . Serious , nonhealing dehisce wound , active ulcer , untreated bone fracture 38 . Proteinuria , demonstrate urine dipstick &gt; 1.0 g protein 24hour urine collection . All patient &gt; /= 2+ protein dipstick urinalysis baseline must undergo 24hour urine collection protein . 39 . Appendiceal adenocarcinoma basket . Complete partial bowel obstruction 40 . EpsteinBarr Virusassociated nasopharyngeal carcinoma basket . a. none 41 . Human Papilloma Virusassociated cancer basket . None 42 . Merkel Cell Carcinoma basket 43 . Neuroendocrine tumor , pancreatic basket 1 . Grade 3 , poorly differentiate neuroendocrine carcinoma 2 . Large cell small cell histology 44 . Neuroendocrine tumor , extrapancreatic basket a. Grade 3 , poorly differentiate neuroendocrine carcinoma b . Large cell small cell histology 45 . Peritoneal mesothelioma basket . None 46 . Pleural mesothelioma basket . None</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Malignant neoplasm digestive organ</keyword>
	<keyword>Malignant neoplasm lip oral cavity pharynx</keyword>
	<keyword>Malignant neoplasms mesothelial soft tissue</keyword>
	<keyword>Malignant neoplasms respiratory intrathoracic organ</keyword>
	<keyword>Rare Solid Tumors</keyword>
	<keyword>Atezolizumab</keyword>
	<keyword>MPDL3280A</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>Anti-VEGF monoclonal antibody</keyword>
	<keyword>rhuMAb-VEGF</keyword>
	<keyword>Phone call</keyword>
</DOC>